Cognition Therapeutics Reports Third Quarter 2026 Results
The Purchase, New York-based biotech posted a $4.1 million net loss and said its cash supports operations into late 2027.
Updated on Nov. 5, 2026 in Alzheimer’s
Cognition Therapeutics reported financial results for the quarter ended September 30, 2026, showing roughly $31.5 million in cash and restricted cash equivalents. The company also said it completed a trial protocol for a planned registrational study of zervimesine in dementia with Lewy bodies.
Why it matters
The quarter's figures show how the company is funding late-stage development of its Alzheimer's-related compound while its grant support winds down. Investors and patients watching dementia drug development will look to the timing of upcoming trial readouts.
The company reported $31.5 million in cash and restricted cash equivalents and $18.2 million in remaining obligated National Institute on Aging grant funds as of September 30, 2026. Its third-quarter net loss of $4.1 million, or $(0.04) per share, compares with research spending that rose to $5.1 million, and the filing does not address how long the grant funding will continue beyond those obligated amounts.
The players
Cognition Therapeutics
A clinical-stage biotechnology company based in Purchase, New York, developing zervimesine, a compound studied for Alzheimer's disease and dementia with Lewy bodies.
U.S. Food and Drug Administration
The federal agency whose Office of Neuroscience worked with the company during 2026 on the registrational trial protocol for zervimesine.
The details
Cognition Therapeutics completed a trial protocol for a registrational study of zervimesine in dementia with Lewy bodies, developed with the Office of Neuroscience at the FDA during 2026. The company also said the FDA aligned with it on primary and key secondary endpoints for a Phase 3 trial, and a poster developed with the Alzheimer's Clinical Trials Consortium was accepted for presentation at the CTAD annual meeting.
Timeline
2026: Work with the FDA on the registrational trial protocol for zervimesine takes place.
September 30, 2026: Third quarter ends with the reported cash position.
November 5, 2026: Financial results and business update are released.
Second half of 2027: Top-line results from the Phase 2 START study are anticipated.
Health Landscape
The company's shift away from National Institute on Aging grant support toward its own cash reserves mirrors a common path for Alzheimer's drug developers that depend on federal research funding before advancing to pivotal trials. Its planned registrational study for dementia with Lewy bodies, a condition affecting an estimated 1.4 million Americans, reflects how the field is expanding beyond Alzheimer's disease itself.
For people and families affected by dementia with Lewy bodies, the planned registrational study signals a possible path toward a future treatment option, though no new therapy is available yet. Patients and caregivers should continue working with their clinicians on current symptom management while clinical trial timelines unfold.
The takeaway
Watching a company's cash runway alongside its trial milestones helps readers judge whether promising dementia research has the funding to reach patients. The coming START results will be the first major test of whether the program advances as planned.
What happens next
Top-line results from the Phase 2 START study are expected in the second half of 2027, and the company estimates its cash will fund operations into the fourth quarter of 2027.
Further reading
For broader context on drug development for memory disorders, see Alzheimer's coverage in New York.
